항균약 내성 시장 : 규모 조사, 약제 클래스별, 적응증별, 작용기전별, 지역별 예측(2022년-2032년)

Global Antimicrobial Resistance Market is valued approximately at USD 4.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.6% over the forecast period 2024-2032. Antimicrobial resistance (AMR) represents a profound challenge in contemporary healthcare, driven predominantly by the misuse and overuse of antibiotics. This misuse is rampant, particularly in low- and middle-income countries where regulatory frameworks are often weak or poorly enforced, leading to overprescribing and unregulated antibiotic use. Consequently, this contributes to the escalating demand for novel antibiotics capable of combating resistant bacterial infections. The urgent need for new antibiotics that can overcome antimicrobial resistance stems from the growing ineffectiveness of existing drugs. This resistance incurs substantial economic costs and places significant burdens on healthcare systems, often resulting in prolonged hospital stays and intensive care requirements. Antimicrobial resistance arises when microorganisms such as bacteria, fungi, and viruses develop resistance to drugs designed to kill them, posing severe threats to global health by making infections harder to treat and increasing the risk of disease spread, severe illness, and mortality.

Several factors propel the growth of the antimicrobial resistance market. The misuse and overuse of antibiotics, combined with the rising prevalence of difficult-to-treat bacterial infections, are primary drivers. The World Health Organization (WHO) has highlighted antimicrobial resistance as one of the top ten global public health threats, underscoring the urgent need for novel antibiotics. Complicated infections such as urinary tract infections (cUTIs) and hospital-acquired pneumonias caused by resistant bacteria exemplify the challenge, as they involve pathogens with limited treatment options, necessitating the development of new antibiotics to address these critical needs. The market is also bolstered by significant investments from key players focused on developing and launching new antibiotics. Products like Dificid, Recarbrio, Zerbaxa, and others are increasingly adopted in developed and some developing countries, driven by their effectiveness against resistant bacteria. However, the high cost associated with these novel antibiotics, due to complex R&D processes and stringent regulations, poses a significant market restraint. Furthermore, increased awareness of antibiotic resistance and substantial funding for developing new antibiotics present lucrative growth opportunities. Collaborations and partnerships among key players further boost market prospects.

The key region in the Antimicrobial Resistance Market includes North America, Europe, Asia Pacific, Latin America, Middle East & Africa. In 2023, North America dominates the antimicrobial resistance market, attributed to the presence of major industry players, advanced healthcare infrastructure, and the launch of novel antibiotics. the region's robust healthcare infrastructure and advanced pharmaceutical industry enable extensive research and development in combating AMR. Leading pharmaceutical companies based in the United States and Canada spearhead innovation in antibiotics and alternative therapies, supported by significant investments in drug discovery and clinical trials. In addition, North America's stringent regulatory frameworks ensure rigorous testing and approval processes for new antimicrobial agents, maintaining high standards of efficacy and safety. Moreover, widespread awareness campaigns and public health initiatives across the continent emphasize responsible antibiotic use and infection prevention strategies, aiming to curb the rise of resistant pathogens. The Asia-Pacific region is expected to witness the highest growth rate, driven by excessive antibiotic misuse, rising healthcare awareness, and the adoption of novel antibiotic medications in countries like India and China.

Major market players included in this report are:

• Alkem Laboratories Ltd
• Innoviva, Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Acurx Pharmaceuticals, Inc.
• Basilea Pharmaceutica Ltd
• Cumberland Pharmaceuticals Inc.
• Wockhardt Limited
• Paratek Pharmaceuticals, Inc.
• Nabriva Therapeutics plc

The detailed segments and sub-segment of the market are explained below:

By Drug Class

• Combination Therapies
• Tetracyclines
• Cephalosporins
• Glycopeptides and Lipoglycopeptides
• Oxazolidinones
• Others

By Indication

• Complicated Urinary Tract Infections (cUTI)
• Blood Stream Infections
• Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
• Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP and VABP)
• Community Acquired Pneumonia (CAP)
• Others

By Mechanism of Action

• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• Others

By Pathogen

• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Staphylococcus aureus
• Enterococcus Spp
• Others
• Escherichia coli

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand-side and supply-side analysis of the market.

Table of Contents

Chapter 1. Global Antimicrobial Resistance Market Executive Summary

• 1.1. Global Antimicrobial Resistance Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Class
  • 1.3.2. By Indication
  • 1.3.3. By Mechanism of Action
  • 1.3.3. By Pathogen
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Antimicrobial Resistance Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Antimicrobial Resistance Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Misuse and Overuse of Antibiotics
  • 3.1.2. Rising Prevalence of Resistant Bacterial Infections
  • 3.1.3. Increasing Demand for Novel Antibiotics
• 3.2. Market Challenges
  • 3.2.1. High Cost of Novel Antibiotics
  • 3.2.2. Regulatory Hurdles in Antibiotic Development
• 3.3. Market Opportunities
  • 3.3.1. Technological Advancements in Antibiotic Development
  • 3.3.2. Increased Funding and Collaboration

Chapter 4. Global Antimicrobial Resistance Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Antimicrobial Resistance Market Size & Forecasts by Drug Class 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Antimicrobial Resistance Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Combination Therapies
  • 5.2.2. Tetracyclines
  • 5.2.3. Cephalosporins
  • 5.2.4. Glycopeptides and Lipoglycopeptides
  • 5.2.5. Oxazolidinones
  • 5.2.6. Others

Chapter 6. Global Antimicrobial Resistance Market Size & Forecasts by Indication 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Antimicrobial Resistance Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Complicated Urinary Tract Infections (cUTI)
  • 6.2.2. Blood Stream Infections
  • 6.2.3. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • 6.2.4. Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP and VABP)
  • 6.2.5. Community Acquired Pneumonia (CAP)
  • 6.2.6. Others

Chapter 7. Global Antimicrobial Resistance Market Size & Forecasts by Mechanism of Action 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Antimicrobial Resistance Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Protein Synthesis Inhibitors
  • 7.2.2. Cell Wall Synthesis Inhibitors
  • 7.2.3. Others

Chapter 8. Global Antimicrobial Resistance Market Size & Forecasts by Pathogen 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Antimicrobial Resistance Market: Pathogen Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Escherichia coli
  • 8.2.2. Klebsiella pneumoniae
  • 8.2.3. Pseudomonas aeruginosa
  • 8.2.4. Staphylococcus aureus
  • 8.2.5. Enterococcus Spp
  • 8.2.6. Others

Chapter 9. Global Antimicrobial Resistance Market Size & Forecasts by Region 2022-2032

• 9.1. North America Antimicrobial Resistance Market
  • 9.1.1. U.S. Antimicrobial Resistance Market
    • 9.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Indication breakdown size & forecasts, 2022-2032
    • 9.1.1.3. Mechanism of Action breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Antimicrobial Resistance Market
• 9.2. Europe Antimicrobial Resistance Market
  • 9.2.1. U.K. Antimicrobial Resistance Market
  • 9.2.2. Germany Antimicrobial Resistance Market
  • 9.2.3. France Antimicrobial Resistance Market
  • 9.2.4. Spain Antimicrobial Resistance Market
  • 9.2.5. Italy Antimicrobial Resistance Market
  • 9.2.6. Rest of Europe Antimicrobial Resistance Market
• 9.3. Asia-Pacific Antimicrobial Resistance Market
  • 9.3.1. China Antimicrobial Resistance Market
  • 9.3.2. India Antimicrobial Resistance Market
  • 9.3.3. Japan Antimicrobial Resistance Market
  • 9.3.4. Australia Antimicrobial Resistance Market
  • 9.3.5. South Korea Antimicrobial Resistance Market
  • 9.3.6. Rest of Asia Pacific Antimicrobial Resistance Market
• 9.4. Latin America Antimicrobial Resistance Market
  • 9.4.1. Brazil Antimicrobial Resistance Market
  • 9.4.2. Mexico Antimicrobial Resistance Market
  • 9.4.3. Rest of Latin America Antimicrobial Resistance Market
• 9.5. Middle East & Africa Antimicrobial Resistance Market
  • 9.5.1. Saudi Arabia Antimicrobial Resistance Market
  • 9.5.2. South Africa Antimicrobial Resistance Market
  • 9.5.3. Rest of Middle East & Africa Antimicrobial Resistance Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Alkem Laboratories Ltd
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Innoviva, Inc.
  • 10.3.3. Pfizer Inc.
  • 10.3.4. Merck & Co., Inc.
  • 10.3.5. Acurx Pharmaceuticals, Inc.
  • 10.3.6. Basilea Pharmaceutica Ltd
  • 10.3.7. Cumberland Pharmaceuticals Inc.
  • 10.3.8. Wockhardt Limited
  • 10.3.9. Paratek Pharmaceuticals, Inc.
  • 10.3.10. Nabriva Therapeutics plc

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes